Better Health for All

Regeneron's core business is dedicated to discovering, developing, manufacturing, and commercializing medicines for serious diseases, with approved medicines and 45 product candidates designed to help patients across various conditions

. This indicates that its entire business is devoted to health improvement. Regeneron acquired 23andMe for $256 million to enhance genetic research for personalized treatments and invested $120 million in Truveta to create a large genetic database for drug discovery and patient care . During the COVID-19 pandemic, Regeneron demonstrated exceptional crisis response by entering an agreement to develop a next-generation monoclonal antibody therapy . The company's operations do not involve food or nutritional products, nor do its products have addiction potential.

Fair Money & Economic Opportunity

Regeneron Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines. The company does not offer lending, insurance, or deposit services to consumers, nor does it operate as a financial institution. Consequently, all Key Performance Indicators (KPIs) under the 'Fair Money & Economic Opportunity' value, which are designed to evaluate financial products, pricing, fees, lending compliance, customer debt, and financial literacy initiatives, are not applicable to Regeneron's core business model. While Regeneron undertakes various corporate social responsibility efforts, including STEM education

, patient assistance programs , and diversity, equity, and inclusion initiatives , these do not align with the specific definitions of the financial services-focused KPIs.

Fair Pay & Worker Respect

In 2021, Regeneron was certified by Great Place To Work®, with 89% of employees affirming it as a great workplace, which is significantly higher than the 57% average for U.S.-based companies.

Furthermore, 95% of employees expressed pride in their work and the company's community contributions.

Fair Trade & Ethical Sourcing

No specific evidence was found in the provided articles to assess Regeneron Pharmaceuticals Inc. against the KPIs for Fair Trade & Ethical Sourcing. The articles mention general commitments to ethical practices and sustainability

, inclusion in the Dow Jones Sustainability World Index , and an internal Ethics & Integrity program with monitoring activities . However, they do not provide quantitative data on fair-trade certified spend, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, high-risk material spend, or supplier diversity spend.

Honest & Fair Business

Regeneron Pharmaceuticals received an S&P Global ESG Score of 51 as of September 09, 2025.

The company has not incurred any ethics-related regulatory fines in the past three years. However, it is currently facing accusations from the U.S. Department of Justice regarding alleged false average sales price reports for its drug Eylea from 2012 to 2023, and a securities fraud class action lawsuit related to similar allegations. Regeneron has a comprehensive whistleblower policy, including an Open Door policy, an anonymous and confidential 24-hour hotline, and an online reporting system (EthicsPoint). Employees are encouraged to report concerns without fear of retaliation, and annual or regular training is provided. Reports of suspected non-compliance are promptly investigated and corrective action is taken. The effectiveness of this program is not publicly measured. Regeneron maintains a zero-tolerance anti-corruption policy that prohibits all forms of bribery, including facilitation payments, globally. The policy complies with laws like the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act, requires annual certification from all colleagues, and mandates due diligence and screening for third parties and distributors.

Kind to Animals

Regeneron Pharmaceuticals is listed on the Cruelty Free Investing animal use list, indicating that none of its products are certified cruelty-free.

The company engages in animal testing, and its public policy commits to the Three Rs (Replacement, Reduction, and Refinement) principles, but lacks measurable goals or accountability for reduction. All research involving live animals requires approval by the Institutional Animal Care and Use Committee (IACUC) and adheres to U.S. federal and state laws, including the Animal Welfare Act and Public Health Service Policy. Regeneron's animal care and use program has received full accreditation from AAALAC International.

No War, No Weapons

Regeneron allocated approximately 0.17% of its $13.1 billion 2023 revenue to peacebuilding-related initiatives

, including $21 million in donations to nonprofit organizations and a $1 million annual investment in STEM education in Nashville . The company states it is aligned with the U.N.’s Guiding Principles on Business and Human Rights , and its Compliance Program is overseen by the Corporate Governance and Compliance Committee of the Board of Directors . Regeneron holds its suppliers to high ethical and labor standards , reflected in its Vendor Code which includes human rights . It has a zero-tolerance policy against human trafficking , stating that any supplier found to use forced labor or human trafficking would be terminated , and monitors suppliers' conflict mineral traceability . The company does not develop or sell dual-use products with both civilian and military applications.

Planet-Friendly Business

Regeneron's total Scope 1, 2, and 3 greenhouse gas emissions were 1,465,520 metric tons CO2e in 2024, representing a 50.7% increase from 2023.

The company has postponed setting science-based targets. As of December 2024, 65.2% of total energy consumption was sourced from renewable energy. Regeneron achieved a 99% waste diversion rate in 2024, with zero hazardous waste sent to landfill in 2023. The company reported no environmental compliance violations resulting in penalties. Nearly 80% of Regeneron’s 216 acres of operational land in New York and Ireland comprises undeveloped land, wetlands, woodlands, water, and historically protected heritage sites. Regeneron publishes its fifth annual Task Force on Climate-related Financial Disclosures (TCFD) Report. Its 2020 climate scenario analysis considered only a business-as-usual 4.1°C warming scenario, focusing on physical risks and omitting transition risks.

Respect for Cultures & Communities

Regeneron Pharmaceuticals has no reported cultural appropriation incidents, cultural site disruptions, or cultural incidents requiring a response. The company demonstrates a commitment to community engagement, donating $27.5 million to nonprofit organizations in 2024, with 52% of employees participating in volunteer activities globally.

Regeneron has been recognized on 'The Civic 50' list for eight consecutive years. The company committed $34 million over five years to sponsor ISEF for global student STEM engagement and invested $5 million over five years in Nashville's STEM ecosystem. Regeneron also partnered with Meharry Medical College and others for the 'Together for CHANGE' initiative, committing $20 million to address health disparities and support STEM education for people of African ancestry.

Safe & Smart Tech

Regeneron reported a data breach affecting consumers in May 2024, subsequently implementing additional security measures.

The company's cybersecurity governance includes risk assessments, vulnerability monitoring, and incident response systems, overseen by its board. Regeneron's Data Privacy Philosophy emphasizes transparency, privacy ethics, and data protection, which involves informing individuals about data usage, using personal data for clear purposes, and safeguarding data. In January 2025, Regeneron invested $120 million in Truveta to build a genetic database, where partners will require patient consent for genomic data analysis. The company also announced the acquisition of 23andMe in May 2025, assuring adherence to existing privacy policies and engaging an independent ombudsman to assess the deal's privacy impact.